Compass Pathways Names U.S. Grant Recipients for COMP360 Training
LONDON and NEW YORK — September 10, 2026 Compass Pathways plc announced that five organizations have been awarded grants...
Psychiatry
Advertisement
Definium Therapeutics to Present Phase 3 DT120 Data at Psych Congress
NEW YORK — September 10, 2026 Definium Therapeutics, Inc. announced plans to present six posters and an invited oral...
Compass Pathways Advances COMP360 Toward Potential TRD Launch
LONDON and NEW YORK — September 9, 2026 Compass Pathways plc announced positive topline 52-week open-label results from Part...
Definium Therapeutics Gains FDA Breakthrough Therapy Designation for DT120 in MDD
NEW YORK — September 8, 2026 Definium Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted...
Helus Pharma Completes Phase 3 HLP003 Enrollment in MDD
NEW YORK and TORONTO, Aug. 14, 2026 Helus Pharma is advancing its late-stage clinical development strategy for novel serotonergic...
Advertisements
Mapi Pharma Advances Once-Monthly Cariprazine Depot After Positive Phase I/IIa Results
NESS ZIONA, Israel, August 12, 2026 Mapi Pharma Ltd. announced initial clinical results from its ongoing Phase I/IIa study...
Compass Pathways Partners with VA to Evaluate COMP360 for Treatment-Resistant Depression
LONDON & NEW YORK, August 6, 2026 Definium Therapeutics reported its second quarter 2026 financial results and recent business...
Definium Therapeutics Advances DT120 ODT After Positive Phase 3 Results
NEW YORK, August 6, 2026 Definium Therapeutics reported its second quarter 2026 financial results and recent business highlights, led...
Supernus Pharmaceuticals and Indivior to Merge in $2.2 Billion CNS Biopharma Deal
ROCKVILLE, Md. & RICHMOND, Va., Aug. 3, 2026 Supernus Pharmaceuticals and Indivior Pharmaceuticals announced they have entered into a...
LB Pharmaceuticals Accelerates Phase 3 LB-102 Schizophrenia Timeline
New York, July 22, 2026 LB Pharmaceuticals announced that it now expects to report topline results from the pivotal...
Advertisement
